Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 18Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 2Breast Neoplasms, Male 2Breast Diseases 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sexual Dysfunctions, Psychological 1Recurrence 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Granulosa cell tumor of the ovary 1Endometrial Neoplasms 1Breast Carcinoma In Situ 1Anatomic Stage II Breast Cancer AJCC v8 1Advanced Breast Cancer 1

Interventions

ribociclib 2Specimen Handling 2tucatinib 1trastuzumab biosimilar HLX02 1pertuzumab 1exemestane 1durvalumab 1Trastuzumab 1Taxes 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Immunoglobulin G 1Genetic Testing 1Fulvestrant 1Drug Therapy 1Doxorubicin 1Docetaxel 1Disulfides 1Cyclophosphamide 1Carboplatin 1Anastrozole 12C4 antibody 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anatomic Stage II Breast Cancer AJCC v8 × exemestane × 30 days × Clear all
NCT07391774 2026-05-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
1,978 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡